On the surface science policy may appear to be rather a dry subject, but it is fundamental to academic research and its positive knock-on effect for innovation in industry.
An increasingly large number of humans are walking through the doors at Benevolent AI HQ, fresh faced and ready to join the team
Let’s talk pharmaceutical innovation, and in doing so let’s be honest and perhaps a little controversial. Last year the CEO of Regeneron, Leonard Schleifer, stood up at the Forbes Healthcare Summit in New York and said something surprisingly candid and revealing.
People bustling madly, sleepovers at the office, and tables full of delicious pasta. This can only mean one thing – dinner time. Oh, apparently it’s because Benevolent just hosted its first ever Hackathon?
Recently we welcomed the news that we have officially selected a study name for BenevolentAI's first clinical trial.
In an age where you could soon be legally (and safely) asleep at the wheel thanks to driverless cars will morality in AI go the same way – is the principle of ethics in AI asleep at the wheel?
It’s the last week before Christmas and a good time for reflection, to pause for breath and to think about what the next year will bring.
We are developing and applying AI technology to enhance and accelerate scientific discovery by turning the world’s mass of highly fragmented scientific information into new insight and useable knowledge that ultimately benefits society.
10 years ago I attended a symposium looking at the future of pharmacology and healthcare.
These are truly exciting times for artificial intelligence (“AI”) and bioscience. This month, together with The Crick and Turing Institutes and the Wellcome Trust, we co-hosted the first of what we anticipate will be an annual symposium on ‘Artificial Intelligence in Bioscience’.